ReAlta Secures $40M to Advance First-in-Class Therapy for Fatal Neonatal Brain Injury
核心洞察
ReAlta Life Sciences (搜索) raised $40 million to support the Phase II STAR trial of pegtarazimod in hypoxic ischemic encephalopathy (搜索) (HIE), with topline data expected in Q3 2026.
Pegtarazimod is a first-in-class peptide that blocks two upstream inflammatory pathways, potentially succeeding where single-target predecessors have failed in HIE.
Approximately 1.2 million babies globally develop HIE each year, with up to a 60% fatality rate, and no drug has yet secured approval for this indication.
ReAlta Life Sciences (搜索) has secured $40 million in financing to propel its Phase II STAR trial (NCT05778188) evaluating pegtarazimod, a potential first-in-class therapy for hypoxic ischemic encephalopathy (搜索) (HIE) — a devastating brain injury in newborns caused by oxygen and blood flow deprivation that remains the leading cause of neonatal mortality and long-term neurological disability.
The Virginia-based biopharma will use the funds to accelerate patient recruitment, expand trial sites beyond the current 18 centers, and support regulatory interactions with the FDA, according to Kia Motesharei, Ph.D., President and COO of ReAlta. The financing provides a cash runway "well into 2027," positioning the company through key milestones including topline data readout and early preparation for a potential Phase III program.
"Running a biotech company is not easy. It requires patience," said Howard Berman, Ph.D., Chairman and CEO of ReAlta. "Here at ReAlta, we're putting our time and our effort into very high unmet needs. This is HIE in neonates who otherwise would die or have a significant injury. And so, it comes with a huge responsibility."
A Dual-Mechanism Approach to a Heterogeneous Disease
Pegtarazimod is an astrovirus-derived peptide designed to block upstream cellular inflammation cascades through a multi-pronged mechanism. The drug inhibits complement activation via C1 (搜索) while simultaneously blocking the myeloperoxidase (搜索) (MPO) enzyme and diminishing the formation of neutrophil extracellular traps (NETs).
"Pegtarazimod activates two different inflammatory pathways, while secondarily blocking the MPOs, which allow us to reduce the impact of oxidative stress in infants with HIE," Motesharei explained. This dual-pathway approach distinguishes pegtarazimod from previous drug candidates developed for HIE, which Motesharei noted have failed due to their singular target focus.
The current standard of care for HIE is therapeutic cooling, administered within approximately six hours after birth. ReAlta's trial integrates pegtarazimod administration at the start of cooling, following existing NICU protocols without disrupting established clinical workflows.
Trial Design and Enrollment Challenges
The STAR trial is a mid-stage study assessing the safety and tolerability of intravenous pegtarazimod, along with preliminary efficacy and pharmacokinetics in newborn infants with moderate-to-severe HIE. Patients receive three ascending doses of the drug or placebo daily during the first 72 hours. Primary endpoints focus on the prevalence and severity of treatment-emergent adverse events (TEAEs), as well as the degree of acute brain injury measured by magnetic resonance imaging (MRI) comparing treatment and placebo groups.
Enrolling neonates presents unique operational challenges. "We're recruiting babies right after birth, and we need to get them into our studies within 6 to 10 hours after birth," Motesharei said. "Babies come 24/7. They don't understand holidays or after hours. So being prepared to enroll and having the necessary staff at these trial sites has been challenging."
To address this, ReAlta has engaged leading key opinion leaders as principal investigators and worked closely with hospital NICUs to ensure drug availability and coordinated care teams. The company is also launching an educational website with videos for parents and collaborating with patient advocacy groups to raise awareness.
Regulatory Strategy and Market Potential
ReAlta is pursuing an accelerated approval pathway based on surrogate endpoints, which it will select in coordination with FDA regulators. If successful, pegtarazimod could become both a first-in-class and first-in-disease pharmaceutical for HIE.
"We're talking about a first-in-disease product, so we're working with the FDA to develop a path to an approval that's similar to other products that have also been first of their kind," Motesharei noted, while declining to share specific regulatory discussions due to confidentiality.
The global burden is substantial: researchers estimate that 1.2 million babies develop HIE each year, with up to a 60% fatality rate. In the United States alone, approximately 8,000 newborns are affected annually. Despite this significant unmet need, no drug has yet secured approval for the indication.
Leadership and Strategic Focus
Since joining in March, Berman and Motesharei have narrowed ReAlta's pipeline to concentrate on pegtarazimod in HIE, pausing other programs including evaluation in steroid-refractory acute graft-versus-host disease. "From a commercial perspective, it's very difficult to develop the same compound for multiple indications, so we decided to pursue HIE. That's where the greatest unmet need is," Motesharei said.
The leadership duo brings complementary expertise: Berman's experience includes building and financing biopharma companies through critical development stages, including guiding Coya Therapeutics through its Nasdaq IPO, while Motesharei's background spans senior roles at Merck, Madrigal, and Dyax, where he contributed to the FDA approval of Rezdiffra, the first approved treatment for NASH/MASH.
Recruitment for the STAR trial is expected to complete in late Q3 2026, with topline results anticipated shortly thereafter. Depending on the mid-stage outcomes, ReAlta plans to raise additional funds to initiate a Phase III study.